Study ID: NCCTG N0872
Description:

Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma

Location:
Sioux Falls Region,Fargo Region,Bismarck Region,Bemidji Clinic
Principal Investigator:
Miroslaw Mazurczak MD;Miroslaw Mazurczak MD,Preston Steen MD
Disease:
Brain and Nervous System
Stage:
Phase I/II

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list